PARTNER B Does Not Disappoint, According to Citi

Citigroup writes for Edwards Lifescinces EW that the "PARTNER Cohort B trial data forms the basis for the company's PMA filing and we believe SAPIEN will be approved by the FDA in 2H11. Now that the primary endpoint hurdles have been met, we believe the investment debate will shift to market adoption with a focus on support, training and delivery. In addition, we believe new embolic protection devices will also receive attention in order to address vascular and stroke-related complications." Citigroup maintains its Buy rating and $60 price target. Edward Lifesciences closed yesterday at $59.70.